ArticleClinical genitourinary cancer2017
Clinical Outcomes of Perioperative Chemotherapy in Patients With Locally Advanced Penile Squamous-Cell Carcinoma: Results of a Multicenter Analysis.
Article in Clinical genitourinary cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Neoadjuvant Treatment for Penile Cancer: A Systematic Review of Contemporary Evidence.Cancers · 2026Review
- [Current diagnostics and treatment of penile cancer].Urologie (Heidelberg, Germany) · 2026Review
- Neoadjuvant and/or adjuvant immune checkpoint inhibitors combined with chemotherapy for locally advanced resectable penile squamous cell carcinoma.Frontiers in immunology · 2026Article
- Systemic Chemotherapy in Penile Squamous Cell Carcinoma: Mechanisms, Clinical Applications, and Evidence-Based Regimens.Cancers · 2025Review
- [Organ preservation or radical surgery? Modern surgical concepts within the complex interplay between function and oncology].Urologie (Heidelberg, Germany) · 2025Review
- [Innovative systemic treatment approaches for advanced penile cancer].Urologie (Heidelberg, Germany) · 2025Article
- Comparison of efficacy and prognosis between neoadjuvant chemotherapy and adjuvant chemotherapy in penile cancer patients with regional lymph node metastasis.Frontiers in oncology · 2025Article
- Prophylactic inguinal lymphadenectomy for high-risk cN0 penile cancer: The optimal surgical timing.Frontiers in oncology · 2023Article
- HPV-associated penile cancer: Impact of copy number alterations in miRNA/mRNA interactions and potential druggable targets.Cancer biomarkers : section A of Disease markers · 2021Observational
- Nomograms to predict overall and cancer-specific survival in patients with penile cancer.Translational cancer research · 2020Article
- Primary Penile Cancer: The Role of Adjuvant Radiation Therapy in the Management of Extranodal Extension in Lymph Nodes.European urology focus · 2019Article
- Neoadjuvant chemotherapy for penile cancer enabling organ preservation: A case of individualized management for bilateral lymph node metastasis and a bulky primary tumor.Urology case reports · 2019Article
- The Diagnosis and Treatment of Penile Cancer.Deutsches Arzteblatt international · 2018Article
- The case for nonsurgical therapy of nonmetastatic penile cancer.Nature reviews. Urology · 2018Review
- The relationship between HPV status and chemoradiotherapy in the locoregional control of penile cancer.World journal of urology · 2018Article
- Treatment Trends and Outcomes for Patients With Lymph Node-Positive Cancer of the Penis.JAMA oncology · 2018Article
- Neoadjuvant chemotherapy for patients with locally advanced penile cancer: an updated evidence.Asian journal of andrologyArticle
- Novel Role Of DSNB in Staging of Primary Urethral Cancer: New Standard?International braz j urol : official journal of the Brazilian Society of UrologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Funding
Abstract
backgroundThe prognosis of patients with locally advanced penile squamous-cell carcinoma is primarily related to the extent of lymph node metastases. Surgery alone yields suboptimal results, and there is a paucity of data on these patients' outcomes. PATIENTS AND
methodsThis retrospective study evaluated patients who received neoadjuvant or adjuvant chemotherapy from 1990 onward at 12 centers. Cox models were used to investigate prognostic factors for relapse-free survival and overall survival (OS).
resultsAmong the 201 included patients, 39 (19.4%) had disease of T3-4 and N0 clinical stage; the remaining patients had clinical lymph node involvement (cN+). Ninety-four patients received neoadjuvant chemotherapy (group 1), 78 received adjuvant chemotherapy (group 2), and 21 received both (group 3). Eight patients for whom the timing of perioperative chemotherapy administration was unavailable were included in the Cox analyses. Forty-three patients (21.4%) received chemoradiation. Multivariate analysis for OS (n = 172) revealed bilateral disease (P = .035) as a negative prognostic factor, while pelvic cN+ tended to be nonsignificantly associated with decreased OS (P = .076). One-year relapse-free survival was 35.6%, 60.6%, and 45.1% in the 3 groups, respectively. One-year OS was 61.3%, 82.2%, and 75%, respectively. No significant differences were seen on univariable analyses for OS between the groups (P = .45). Platinum type of chemotherapy and chemoradiation were not significantly associated with any outcome analyzed.
conclusionBenchmark survival estimates for patients receiving perioperative chemotherapy for locally advanced penile squamous-cell carcinoma have been provided, with no substantial differences observed between neoadjuvant and adjuvant administration. This analysis may result in improved patient information, although prospective studies are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.